These novel therapies , Tirzepatide , represent a significant advancement in managing obesity and conceivably related disorders. They all are classified as GLP-1 receptor stimulators, signifying they function to mimic the body's GLP-1 hormone , enhancing metabolic secretion and suppressing hunger